Latest News for: malformations
Edit
MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from its Phase 3 study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Pharmiweb 17 Mar 2026
Palvella is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S.
Edit
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with ...
Nasdaq Globe Newswire 10 Mar 2026
BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers, and healthcare professionals ... .
Edit
New study reveals hidden kidney dysfunction in children with cloacal malformations - Children's National (Children's National Medical Center Inc)
Public Technologies 26 Feb 2026
Edit
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations (Form 8-K) (Palvella Therapeutics Inc)
Public Technologies 24 Feb 2026
... anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas.
Edit
Vascular Malformations Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in ...
GetNews 19 Feb 2026
Inactive Products Vascular Malformations Key Companies Vascular Malformations Key Products Vascular Malformations- Unmet Needs Vascular Malformations- Market Drivers and Barriers Vascular ...
Edit
Man regains his eyesight after rare facial malformation operation at Greater Noida hospital
The Times of India 18 Feb 2026
Edit
Man regains his eyesight after complex surgery for rare facial malformation in Greater Noida
The Times of India 18 Feb 2026- 1